BMPs and gene therapy for spinal fusion: Summary statement

Harvinder S. Sandhu; Scott D. Boden; Howard An; James Kang; James Neil Weinstein

doi:10.1097/01.brs.0000076903.10966.86

BMPs and gene therapy for spinal fusion: Summary statement

Harvinder S. Sandhu, Scott D. Boden, Howard An, James Kang, James Neil Weinstein

Research output: Contribution to journal › Short survey › peer-review

10 Scopus citations

Abstract

The use of biologic technologies to engender spinal fusion is at various stages of scientific and clinical development. Recombinant human bone morphogenetic protein 2 is now available for clinical use in anterior lumbar intervertebral fusion and has been extensively studied in other spinal fusion applications. Recombinant bone morphogenetic protein 7 is under examination in regulated clinical trials. Gene therapy technologies are in the preclinical stage of development. In time, biologic interventions will continue to capture greater roles in the treatment of spinal disease.

Original language	English (US)
Pages (from-to)	S85
Journal	Spine
Volume	28
Issue number	15 SUPPL.
DOIs	https://doi.org/10.1097/01.brs.0000076903.10966.86
State	Published - Aug 1 2003

ASJC Scopus subject areas

Clinical Neurology
Orthopedics and Sports Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/01.brs.0000076903.10966.86

Cite this

@article{de25ff506b7543d2b02b2950cc2856ef,

title = "BMPs and gene therapy for spinal fusion: Summary statement",

abstract = "The use of biologic technologies to engender spinal fusion is at various stages of scientific and clinical development. Recombinant human bone morphogenetic protein 2 is now available for clinical use in anterior lumbar intervertebral fusion and has been extensively studied in other spinal fusion applications. Recombinant bone morphogenetic protein 7 is under examination in regulated clinical trials. Gene therapy technologies are in the preclinical stage of development. In time, biologic interventions will continue to capture greater roles in the treatment of spinal disease.",

author = "Sandhu, {Harvinder S.} and Boden, {Scott D.} and Howard An and James Kang and Weinstein, {James Neil}",

year = "2003",

month = aug,

day = "1",

doi = "10.1097/01.brs.0000076903.10966.86",

language = "English (US)",

volume = "28",

pages = "S85",

journal = "Spine",

issn = "0362-2436",

publisher = "Lippincott Williams and Wilkins",

number = "15 SUPPL.",

}

TY - JOUR

T1 - BMPs and gene therapy for spinal fusion

T2 - Summary statement

AU - Sandhu, Harvinder S.

AU - Boden, Scott D.

AU - An, Howard

AU - Kang, James

AU - Weinstein, James Neil

PY - 2003/8/1

Y1 - 2003/8/1

N2 - The use of biologic technologies to engender spinal fusion is at various stages of scientific and clinical development. Recombinant human bone morphogenetic protein 2 is now available for clinical use in anterior lumbar intervertebral fusion and has been extensively studied in other spinal fusion applications. Recombinant bone morphogenetic protein 7 is under examination in regulated clinical trials. Gene therapy technologies are in the preclinical stage of development. In time, biologic interventions will continue to capture greater roles in the treatment of spinal disease.

AB - The use of biologic technologies to engender spinal fusion is at various stages of scientific and clinical development. Recombinant human bone morphogenetic protein 2 is now available for clinical use in anterior lumbar intervertebral fusion and has been extensively studied in other spinal fusion applications. Recombinant bone morphogenetic protein 7 is under examination in regulated clinical trials. Gene therapy technologies are in the preclinical stage of development. In time, biologic interventions will continue to capture greater roles in the treatment of spinal disease.

UR - http://www.scopus.com/inward/record.url?scp=0041565461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041565461&partnerID=8YFLogxK

U2 - 10.1097/01.brs.0000076903.10966.86

DO - 10.1097/01.brs.0000076903.10966.86

M3 - Short survey

C2 - 12897479

AN - SCOPUS:0041565461

SN - 0362-2436

VL - 28

SP - S85

JO - Spine

JF - Spine

IS - 15 SUPPL.

ER -

BMPs and gene therapy for spinal fusion: Summary statement

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this